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MaOBJECTIVES The aim of this study was to describe the natural history and clinical importance of paravalvularaortic regurgitation (PVAR) after CoreValve transcatheter aortic valve replacement (TAVR) and to relate these ﬁndings to
the structural and hemodynamic changes documented by serial echocardiographic analysis.BACKGROUND PVAR after TAVR with the self-expanding CoreValve bioprosthesis has been shown to regressover time, but the time course and the mechanism of PVAR regression has not been completely characterized.METHODS Patients with severe aortic stenosis who underwent CoreValve TAVR and followed up to 1 year inthe multicenter CoreValve U.S. Pivotal Trial (Safety and Efﬁcacy Study of the Medtronic CoreValve System in the
Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve
Replacement) were studied. Serial echocardiography studies were analyzed by an echocardiographic core laboratory.
Annular sizing ratio was calculated from computed tomography measurements. Paired, as well as total, data were
compared.RESULTS The CoreValve was implanted in 634 patients with a mean age of 82.7  8.4 years. After a marked
improvement noted at discharge, aortic valve velocity, mean gradient, and effective oriﬁce area further improved
signiﬁcantly at 1 month (2.08  0.45 m/s vs. 1.99  0.46 m/s, p < 0.0001, 9.7  4.4 mm Hg vs. 8.9  4.6 mm Hg,
p < 0.0001, and 1.78  0.51 cm2 vs. 1.85  0.58 cm2, p ¼ 0.03, respectively). The improvement was sustained through
1 year. PVAR was moderate or severe in 9.9%, and of 36 patients with moderate PVAR at discharge and paired data,
30 (83%) improved at least 1 grade of regurgitation at 1 year. Annular sizing ratio was signiﬁcantly associated with the
degree of PVAR.CONCLUSIONS There was further improvement in aortic prosthetic valve hemodynamics and regression ofPVAR up to 1 year compared with discharge after TAVR with CoreValve. These changes are possibly due to remodeling
and outward expansion of the self-expandable CoreValve with nitinol frame. (Safety and Efﬁcacy Study of the Medtronic
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ABBR EV I A T I ON S
AND ACRONYMS
AR = aortic regurgitation
AS = aortic stenosis
AV = aortic valve
EF = ejection fraction
EOA = effective oriﬁce area
IQR = interquartile range
LV = left ventricle/ventricular
LVEF = left ventricular
ejection fraction
LVOT = left ventricular
outﬂow tract
PVAR = paravalvular aortic
regurgitation
SV = stroke volume
TAVR = transcatheter aortic
valve replacement
VARC = Valve Academic
Research Consortium
VTI = velocity time integral
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1366P atients with severe aortic stenosis(AS) at extreme risk for surgicalaortic valve (AV) replacement have
substantially improved outcomes with tran-
scatheter aortic valve replacement (TAVR)
(1–3). However, paravalvular aortic regurgi-
tation (PVAR) remains a major complication
of TAVR, and its clinical impact varies
depending on the patient population and
type of valve. In the PARTNER (Placement of
Aortic Transcatheter Valves) trial with inop-
erable patients, moderate-to-severe PVAR,
which occurred in 10% of patients after
TAVR, had a trend toward higher all-cause
mortality at 1 year (2). In high-risk patients,
even mild PVAR was associated with poor
survival (4,5). In the CoreValve U.S. Pivotal
Trial (Safety and Efﬁcacy Study of the Med-
tronic CoreValve System in the Treatment of
Symptomatic Severe Aortic Stenosis in High
Risk and Very High Risk Subjects Who Need
Aortic Valve Replacement), there was agradual lessening of the severity of PVAR after
TAVR with the CoreValve bioprosthesis (Medtronic,
Minneapolis, Minnesota), and only severe PVAR
was associated with increased 1-year mortality (3).SEE PAGE 1376One possible contributor to the limited association be-
tween PAVR and mortality in the CoreValve trial is
that continuous aortic root remodeling by the self-
expanding CoreValve bioprosthesis occurs after
implantation. To validate the remodeling hypothesis,
serial echocardiography studies obtained at multi-
ple scheduled follow-up periods were analyzed,
including the forward-ﬂow hemodynamic perfor-
mance of the bioprosthesis over time, the prevalence
and longitudinal follow-up of PVAR, and the anatomic
changes observed as a result of TAVR with a self-
expanding valve with a nitinol frame.
METHODS
PATIENT POPULATION. We evaluated all patients at
extreme surgical risk in the CoreValve U.S. Pivotal
Trial undergoing TAVR. Inclusion and exclusion
criteria and study details have been previously
described (3). The study protocol was approved by the
institutional review board of all participating clinical
sites, and all patients provided written, signed
consent.
ECHOCARDIOGRAPHY. Echocardiography was per-
formed at baseline, post-procedure, hospital dis-
charge, and 1, 6, and 12 months. All echocardiographystudies were centrally analyzed using Digisonics
workstation (Digisonics, Houston, Texas) by the
echocardiography core laboratory at the Mayo Clinic
(Rochester, Minnesota). A level 3–trained physician
echocardiographer approved all measurements that
were performed by sonographers, and determined
valvular regurgitation severity, including PVAR, in
all studies. Measurements were made from an
average of 3 cardiac cycles in sinus rhythm and 3 to 5
cycles in atrial ﬁbrillation. Assessment of the native
AV and the bioprosthesis were made according
to the original Valve Academic Research Con-
sortium (VARC-1), American Society of Echocardiog-
raphy, and European Association of Echocardiography
(6–9). Measurements for left ventricular (LV) vol-
umes, ejection fraction (EF), stroke volume (SV), and
mass were performed according to published guide-
lines (10–12).
LV volume and EF were measured primarily from
the biplane Simpson method, whenever possible.
When LV volume measurement was not possible, left
ventricular ejection fraction (LVEF) was measured
using LV dimensions and also visually estimated by a
physician echocardiographer. LV mass was derived
from the established formula (6,10). Diastolic func-
tion was assessed mainly by mitral inﬂow velocities
because LV relaxation or mitral annulus early dia-
stolic velocity is expected to be reduced in elderly
patients with severe AS, as recommended jointly by
the American Society of Echocardiography and Eu-
ropean Association of Echocardiography (13).
Aortic pressure gradient was calculated as: (4 
[peak aortic valve velocity2  LVOT velocity2]). When
there was a dynamic left ventricular outﬂow tract
(LVOT) gradient, aortic and LVOT velocities were not
used. When there was accelerated ﬂow velocity due
to the position of the sample volume too close to the
native AV or to the skirt of the CoreValve, LVOT
velocity was not used.
The LVOT diameter of the native AV was
measured within 5 mm of the aortic annulus, and
after TAVR, was measured from the outer to the
outer aspect of the bioprosthesis from the para-
sternal long-axis view (8). The AV effective oriﬁce
area (EOA) was calculated according to the continu-
ity equation as: (LVOT diameter)2  0.785  (LVOT
VTI/AV VTI), where VTI is the velocity time integral,
which is equal to SV/AV VTI (11,12). The severity of
aortic regurgitation (AR) was graded based on mul-
tiple parameters including regurgitation color jet
density and width, circumferential extent of turbu-
lent regurgitation color jet around the aortic annulus
for PVAR, and diastolic ﬂow reversal in the
descending aorta. It was classiﬁed as paravalvular or
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1367transvalvular based on the origin of regurgitation.
When the color ﬂow aliasing velocity was low (<50
cm/s), the severity of valvular regurgitation was not
assessed. For PVAR, the circumferential extent from
multiple parasternal short axis views was one crite-
rion in determining severity as recommended by
VARC-1 (7): 1) trivial: a trace of short-lasting (less
than the entire diastole) with usually laminar ﬂow
with or without a trace of regurgitation jet around
the aortic annulus; 2) mild: the circumferential
extent <10% (<36 in clock face), with turbulent AR
jet; 3) moderate: the circumferential of 10% to 20%
(36 to 72); and 4) severe: the circumferential extent
>20% (>72). When there was more than 1 jet, the
values of all regurgitation jets of at least mild degree
were added. Because the circumferential extent
could not be seen in some patients, all available
parameters were used to determine the ﬁnal severity
grading. Pressure–half-time of aortic regurgitant
jet alone was not used to determine severity because
it is neither sensitive nor speciﬁc.
Interobserver and intraobserver variability of
measuring these echocardiography variables was
assessed in a selected cohort of the patients using the
interclass correlation coefﬁcients. For PVAR, the
same number of patients in each severity category
was randomly chosen for variability assessment.
DETERMINATION OF ANNULAR SIZING RATIO. All
patients underwent multidetector computed tomog-
raphy that was analyzed by a central laboratory.
Perimeters of the CoreValve and the aortic annulus
were measured using 3Mensio software, version 5.1
(Pie Medical, Maastricht, the Netherlands). The
annular sizing ratio, which reﬂects incremental bio-
prosthesis diameter as a percentage of the aortic
annulus perimeter, was calculated by the following
formula:
Annular sizing ratio ¼
½ðvalve perimeter  annulus perimeterÞ
=annular perimeter  100
STATISTICAL ANALYSIS. Patients who received suc-
cessful TAVR by either iliofemoral or non-iliofemoral
approach are included in these analyses. Categorical
variables were compared using the Fisher exact test or
the chi-square test, as appropriate. Continuous vari-
ables were presented as mean  SD and compared
using the Student t test or the analysis of variance, as
appropriate. Paired data were compared using paired-
sample t test for continuous variables and Wilcoxon
signed rank sum test for ordinal variables. Survival
curves were constructed using the Kaplan-Meier
method, and compared between groups by gradeof PVAR using the log-rank test. All testing used
a 2-sided alpha level of 0.05. No adjustments were
made for pairwise comparisons among multiple time
points. Statistical analyses were performed using
SAS software, version 9.2 (SAS Institute, Cary,
North Carolina).
RESULTS
PATIENTS. The CoreValve bioprosthesis was
implanted in 634 patients; 486 patients using the
iliofemoral and 148 patients using a non-iliofemoral
approach. Mean age was 82.7  8.4 years, and 52.7%
were women. Mean Society of Thoracic Surgeons
(STS) mortality score was 10.4  5.6%, and 91.8% had
New York Heart Association functional class III to IV
symptoms (Online Table 1).
ECHOCARDIOGRAPHY DATA. Because there were no
substantial differences in any of echocardiography
parameters between iliofemoral and non-iliofemoral
groups, the data for the combined group are dis-
cussed. A summary of the echocardiography ﬁndings
at baseline, hospital discharge, 1 month, 6 months,
and 1 year following TAVR for the entire patient
population is shown in Table 1. To assess the serial
changes more accurately, echocardiography data
paired for baseline and discharge, discharge and
1 month, and discharge and 1 year follow-up were
compared (Table 1, Online Table 2). We also analyzed
serial AV hemodynamic data in 272 patients who had
data at all visits (Online Table 3). Interobserver and
intraobserver variability for hemodynamic parame-
ters and AR are in Online Table 4.
AORTIC REGURGITATION AFTER COREVALVE
IMPLANTATION. Of 634 implanted patients, 52 pa-
tients did not have echocardiography data at dis-
charge due to missing site echocardiogram (n ¼ 27),
poor quality (n ¼ 13), and death (n ¼ 12). Of 582 pa-
tients in whom AR could be assessed at discharge,
total AR was absent or trivial in 284 (48.8%); mild
in 226 (38.8%), moderate in 64 (11.0%), and severe
in 8 (1.4%). Most of the total AR was PVAR, which
was none or trivial, mild, moderate, and severe in
52.1%, 38.0%, 8.6%, and 1.2%, respectively (Table 1).
PVAR was assessed separately in 383 patients
who had paired studies at discharge and 1 year
after the index TAVR procedure. In this matched
dataset at discharge, PVAR was mild, moderate, and
severe in 137 patients (35.8%), 36 (9.4%), and 1
(0.3%), respectively; which changed to 102 (26.6%),
14 (3.7%), and 1 (0.3%) at 1 year (p < 0.0001)
(Figure 1A). Between discharge and 1 year, 170 of
TABLE 1 Echocardiographic Parameters Over Time
Baseline Discharge 1 Month 6 Months 1 Year
p Value From Paired Data
Baseline vs.
Discharge
Discharge vs.
1 Month
Discharge vs.
1 Year
Heart rate, beats/min 70.10  13.03 (632) 74.21  12.37 (593) 70.97  12.81 (559) 68.38  11.66 (470) 67.63  11.31 (419) <0.0001 <0.0001 <0.0001
LV end-systolic diameter, cm 3.33  0.85 (482) 3.24  0.81 (414) 3.27  0.82 (415) 3.27  0.83 (349) 3.33  0.87 (299) <0.0001 0.0024 0.4198
LV end-diastolic diameter, cm 4.94  0.68 (548) 4.93  0.72 (476) 4.92  0.71 (463) 5.00  0.73 (389) 4.97  0.74 (340) 0.4424 0.2498 0.1492
LV end-diastolic volume, ml 113.0 (90.0–144.0) (325) 113.5 (85.0–148.0) (258) 121.0 (93.0–154.0) (261) 111.0 (85.0–151.0) (233) 125.0 (97.0–163.0) (177) 0.5465 0.5797 0.0896
LV end-systolic volume, ml 49.0 (32.0–79.0) (325) 49.0 (32.0–77.0) (257) 52.0 (37.0–79.0) (258) 47.0 (31.0–73.0) (232) 55.0 (40.0–80.0) (176) 0.3651 0.0279 0.0531
2DE SV–calculated, ml 60.28  19.72 (325) 63.11  24.94 (257) 65.36  20.60 (258) 65.18  23.14 (232) 70.03  24.60 (176) 0.0224 0.8214 0.2294
LV ejection fraction–calculated, % 54.18  14.24 (482) 56.80  12.69 (414) 55.60  12.99 (415) 57.32  12.28 (349) 55.67  12.81 (299) <0.0001 0.0005 0.2818
LV ejection fraction–visual
estimate, %
54.58  14.33 (632) 58.09  12.20 (589) 57.05  12.47 (552) 57.93  10.95 (469) 57.36  11.73 (419) <0.0001 0.0002 0.0786
Ventricular septal thickness, mm 12.56  2.31 (538) 12.06  2.18 (470) 11.68  2.14 (456) 11.25  1.91 (383) 10.97  1.81 (331) 0.0004 <0.0001 <0.0001
Posterior wall thickness, mm 11.92  1.95 (540) 11.42  1.87 (469) 11.16  1.81 (452) 10.85  1.67 (382) 10.58  1.79 (328) <0.0001 0.0005 <0.0001
Relative wall thickness 0.49  0.11 (533) 0.47  0.11 (464) 0.46  0.10 (449) 0.44  0.09 (382) 0.43  0.09 (328) 0.0093 0.0012 <0.0001
LV mass index, g/m2 132.32  36.19 (523) 124.32  33.66 (460) 119.84  32.90 (441) 115.61  30.74 (377) 112.17  30.71 (325) <0.0001 0.0003 <0.0001
CoreValve LVOT diameter,
outer to outer, cm
— 2.03  0.24 (558) 2.05  0.27 (532) 2.08  0.23 (438) 2.09  0.23 (401) 0.8055 0.0287 <0.0001
LVOT peak velocity, m/s 0.92  0.21 (573) 1.07  0.22 (552) 1.02  0.21 (532) 1.04  0.21 (442) 1.01  0.20 (397) <0.0001 <0.0001 <0.0001
LVOT velocity time integral 21.66  5.58 (572) 20.86  4.96 (552) 21.06  5.24 (532) 22.12  5.49 (442) 22.04  5.48 (397) 0.0261 0.7965 <0.0001
AV peak velocity, m/s 4.33  0.67 (624) 2.08  0.45 (578) 1.99  0.46 (543) 2.01  0.44 (457) 2.01  0.44 (413) <0.0001 <0.0001 <0.0001
AV velocity time integral, cm 104.45  22.27 (624) 39.06  9.86 (577) 39.37  11.27 (544) 41.66  11.20 (457) 41.80  11.01 (413) <0.0001 0.9365 <0.0001
AV peak gradient, mm Hg 76.69  23.60 (624) 18.17  8.22 (578) 16.72  8.26 (543) 17.00  7.69 (457) 16.88  8.05 (413) <0.0001 <0.0001 <0.0001
AV mean gradient, mm Hg 47.81  15.20 (624) 9.67  4.44 (577) 8.93  4.62 (544) 9.16  4.29 (457) 8.98  4.45 (413) <0.0001 <0.0001 <0.0001
Doppler velocity index 0.211  0.052 (570) 0.550  0.133 (545) 0.557  0.138 (524) 0.547  0.134 (437) 0.546  0.133 (395) <0.0001 0.3597 0.6346
Doppler SV, ml 74.12  23.32 (520) 67.45  20.21 (516) 70.00  22.06 (508) 76.20  23.70 (414) 75.90  23.14 (383) <0.0001 0.0490 <0.0001
Effective oriﬁce area, cm2 0.73  0.24 (518) 1.78  0.51 (509) 1.85  0.58 (500) 1.88  0.54 (409) 1.87  0.54 (381) <0.0001 0.0345 0.0030
Effective oriﬁce area index, cm2/m2 0.40  0.12 (518) 0.99  0.29 (509) 1.03  0.33 (500) 1.04  0.31 (409) 1.03  0.30 (381) <0.0001 0.0362 0.0038
$Moderate total AR, % 9.3 (58/624) 12.4 (72/582) 14.6 (79/540) 8.9 (41/463) 5.8 (24/411) 0.0458 0.1608 0.0005
$Moderate MR, % 17.2 (106/616) 11.7 (68/580) 13.9 (76/548) 9.9 (46/464) 7.7 (32/415) 0.0011 0.2601 0.0420
Total AR 0.4247 0.0147 <0.0001
None/trivial 46.5 (290/624) 48.8 (284/582) 44.3 (239/540) 54.9 (254/463) 64.7 (266/411)
Mild 44.2 (276/624) 38.8 (226/582) 41.1 (222/540) 36.3 (168/463) 29.4 (121/411)
Moderate 9.1 (57/624) 11.0 (64/582) 13.3 (72/540) 8.6 (40/463) 5.6 (23/411)
Severe 0.2 (1/624) 1.4 (8/582) 1.3 (7/540) 0.2 (1/463) 0.2 (1/411)
Paravalvular AR N/A 0.2622 <0.0001
None/trivial — 52.1 (296/568) 49.5 (263/531) 60.0 (276/460) 69.7 (285/409)
Mild — 38.0 (216/568) 39.0 (207/531) 32.6 (150/460) 26.4 (108/409)
Moderate — 8.6 (49/568) 11.1 (59/531) 7.4 (34/460) 3.7 (15/409)
Severe — 1.2 (7/568) 0.4 (2/531) 0.0 (0/460) 0.2 (1/409)
Transvalvular AR N/A 0.0260 0.4011
None/trivial — 94.0 (530/564) 90.8 (481/530) 93.4 (427/457) 93.1 (378/406)
Mild — 4.8 (27/564) 7.9 (42/530) 5.9 (27/457) 6.9 (28/406)
Moderate — 1.1 (6/564) 1.1 (6/530) 0.7 (3/457) 0.0 (0/406)
Severe — 0.2 (1/564) 0.2 (1/530) 0.0 (0/457) 0.0 (0/406)
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1369383 (44%) patients showed improvement in PVAR
by at least 1 grade, and 69 (18%) got worse, mostly
to having mild PVAR. Of 137 patients with mild
PVAR at discharge, 89 (65%) had none to trivial
at 1 year. Of 36 patients with moderate PVAR
at discharge, 30 (83%) improved by at least 1 grade
at 1-year follow-up (Figure 2). The percentage
of patients with none-to-trivial PVAR increased
from 54.6% to 69.5% between discharge and 1-year
follow-up.
Because the severity of PVAR may be associated
with valve sizing, the mean annular sizing ratio was
calculated for 3 patient groups: Group 1 were those
with optimal results with respect to PVAR (i.e., none
or trivial PVAR at both discharge and 1 year), Group 2
patients had mild or greater PVAR at discharge that
improved to none or trivial by 1 year, and Group
3 patients had mild or greater PVAR at 1 year
(Figure 1B). The mean annular sizing ratio was 17.5
 5.9% in Group 1, 15.6  5.3% in Group 2, and 14.2 
5.7% in Group 3 (p < 0.0001).
Severe PVAR at discharge predicted overall mor-
tality, most of which occurred by 1-month follow-up,
but there were no signiﬁcant differences in mortality
among patients with moderate or less PVAR (3).
Because there was a reduction in PVAR severity over
time, overall mortality was reassessed for patients
with adjusted PVAR severity at 1 and 6 months
(Figure 3). There was no signiﬁcant difference in
overall mortality after 6 months among the different
severities of AR.
IMPACT OF COREVALVE IMPLANTATION ON AV
HEMODYNAMICS. AV velocity and mean gradients
improved acutely from 4.33  0.67 m/s at baseline to
2.08  0.45 m/s at discharge (p < 0.0001), and from
47.8  15.2 mm Hg to 9.7  4.4 mm Hg (p < 0.0001),
respectively. EOA increased from 0.73  0.24 cm2 to
1.78  0.51 cm2 (p < 0.0001).
SV calculated by Doppler increased signiﬁcantly
from discharge to 1 year (67.5  20.2 ml vs. 75.9 
23.1 ml, p < 0.0001), whereas heart rate decreased
(74  12 beats/min vs. 68  11 beats/min,
p < 0.0001). Both LVOT VTI and the dimension
from the outer-to-outer edges of the ventricular
end of the CoreValve bioprosthesis increased from
discharge to 1 year (from 20.9  5.0 cm to 22.0 
5.5 cm, and from 2.03  0.24 cm to 2.09  0.23 cm,
respectively, p < 0.0001 for both).
SV derived from LV volume measurements was
slightly smaller than Doppler-measured SV, but
increased similarly (Table 1, Online Figure 1); SV
increase from discharge to 1-year follow-up was
8.4 ml by Doppler, and was 6.9 ml by 2-dimensional
FIGURE 1 PVAR at Discharge and 1 Year
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(A) The proportion of patients with varying degrees of paravalvular aortic regurgitation (PVAR) in 383 patients with paired echocardiography studies available. (B) Mean
annular sizing ratio (100  [valve perimeter  aortic annulus perimeter] / aortic annulus perimeter) for patients without PVAR, with PVAR that regressed by 1 year, and
with residual PVAR that remained at 1 year. Error bars represent standard deviation. AR ¼ aortic regurgitation.
Oh et al. J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 8 , N O . 1 2 , 2 0 1 5
Paravalvular Aortic Regurgitation After TAVR D E C E M B E R 2 0 1 5 : 1 3 6 4 – 7 5
1370volumetric methods. Despite the increase in SV,
there were statistically signiﬁcant reductions in AV
velocity and mean gradient from discharge to
1-month follow-up, from 2.08  0.45 m/s to 1.99 
0.46 m/s, and from 9.7  4.4 mm Hg to 8.9 
4.6 mm Hg, respectively, p < 0.0001 for both
(Table 1). Both variables increased slightly with
further increase in SV at 1 year to 2.01  0.44 m/s
and 9.0  4.5 mm Hg, respectively. EOA increased
from 1.78  0.51 cm2 to 1.87  0.54 cm2 (p ¼ 0.003
for the overall 5% increase). The longitudinalFIGURE 2 Paired PVAR Data at Discharge and 1 Year
   
 None Trivial 
Discharge (N =123) (N =143) 
None 49 18 
Trivial 50 48 
Mild 23 66 
Moderate 1 11 
Severe 0 0 
Improvement in PVAR by at least 1 grade
Worsening in PVAR by at least 1 grade
Of 173 patients with mild (n¼ 137) or moderate (n¼ 36) paravalvular aort
grade at 1-year follow-up. Green ¼ improvement in PVAR by at least 1changes in AV mean gradient and Doppler SV are
shown in Figure 3. Because the change in SV could
have been due to improved LVEF, we also analyzed
the data in patients with an LVEF $50%, and the
results were the same (Online Table 5).
The further hemodynamic improvement with
CoreValve after discharge was similar for all valve
sizes (Table 2).
IMPACT OF COREVALVE IMPLANTATION ON LV
FUNCTION, MASS, AND MITRAL REGURGITATION.
For 203 patients who had an LVEF <50% at baseline,One Year
Mild Moderate Severe
(N =102) (N =14) (N =1)
7 1 0
34 2 0
42 6 0
18 5 1
1 0 0
ic regurgitation (PVAR) at discharge, 119 (69%) improved by at least 1
grade; pink ¼ worsening in PVAR by at least 1 grade.
FIGURE 3 All-Cause Mortality According to PVAR Severity
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Because there was a reduction in PVAR severity over time, all-cause mortality was reassessed for patients with adjusted PVAR severity at
1 and 6 months. There was no signiﬁcant difference in overall mortality among the different severities of PVAR except for severe AR.
Abbreviations as in Figure 2.
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 8 , N O . 1 2 , 2 0 1 5 Oh et al.
D E C E M B E R 2 0 1 5 : 1 3 6 4 – 7 5 Paravalvular Aortic Regurgitation After TAVR
1371we observed signiﬁcant improvement from 37.2 
10.0% to 47.4  12.9% at discharge (p < 0.0001) to 49.1
 12.1% at 1 year. LV mass index gradually decreased
up to 1 year (132 g/m2 at baseline to 112 g/m2 at 1 year,
p < 0.0001) (Table 1). LV diastolic function and ﬁlling
pressure improved gradually, with reduction of me-
dian E/A ratio (from 1.00 [interquartile range (IQR):
0.75 to 1.50] at baseline to 0.87 [IQR: 0.67 to 1.08] at
1 year, p ¼ 0.0004) and prolongation of median
mitral inﬂow deceleration time (from 189 ms [IQR:
157 to 247 ms] to 241 ms [IQR: 191 to 301 ms],
p < 0.0001). The number of patients with moderate
or greater mitral regurgitation decreased from 17.2%
at baseline to 11.7% at discharge (p ¼ 0.001), and to
7.7% at 1 year.
DISCUSSION
Core laboratory analysis of serial echocardiography
examinations in extreme risk patients with severe AS
who underwent TAVR using a self-expandable Core-
Valve bioprosthesis demonstrated the following
results: 1) PVAR of moderate or greater severityoccurred in 9.9% after TAVR, but 83% of patients with
moderate PVAR decreased in severity at 1-year follow-
up, and only severe PVAR was associated with
decreased survival; 2) in addition to acute improve-
ment in AV velocity, mean gradient, and EOA noted at
discharge, these parameters signiﬁcantly improved
further at 1 month and were sustained to 1 year,
whereas SV increased; and 3) the annular sizing ratio
was signiﬁcantly associated with the degree of PVAR.
CONTINUOUS IMPROVEMENT OF COREVALVE
HEMODYNAMICS. Although small, there was statisti-
cally signiﬁcant improvement of CoreValve hemody-
namics with lower bioprosthesis velocity, lower
gradient, and higher EOA at 1 month compared with at
discharge. This improvement occurred while LV SV
increased, with slower heart rate and less mitral
regurgitation. The majority of the SV increase took
place between the 1- and 6-month follow-ups
(Figure 4). After a signiﬁcant reduction at 1 month,
peak AV velocity and mean gradient increased slightly
during that period, but remained signiﬁcantly lower
than discharge values. Because higher AV velocity and
gradient are expected with a higher SV if the EOA
TABLE 2 Echocardiographic Parameters Over Time by Implanted Valve Size
23 mm
(n ¼ 21)
26 mm
(n ¼ 231)
29 mm
(n ¼ 357)
31 mm
(n ¼ 25)
All Sizes
(N ¼ 634)
LVOT diameter outer to outer, cm
Discharge 1.74  0.15 (17) 1.90  0.20 (204) 2.11  0.22 (315) 2.30  0.23 (22) 2.03  0.24 (558)
1 yr 1.87  0.09 (13) 1.96  0.20 (147) 2.18  0.20 (229) 2.34  0.19 (12) 2.09  0.23 (401)
LVOT velocity time integral, cm2
Discharge 23.36  5.32 (17) 22.21  4.87 (203) 20.04  4.80 (309) 18.03  4.06 (23) 20.86  4.96 (552)
1 yr 24.03  5.86 (14) 23.39  5.09 (147) 21.18  5.47 (223) 19.28  5.82 (13) 22.04  5.48 (397)
AV peak velocity, m/s
Discharge 2.61  0.44 (18) 2.04  0.42 (209) 2.07  0.45 (328) 2.23  0.40 (23) 2.08  0.45 (578)
1 yr 2.33  0.57 (13) 2.01  0.43 (153) 1.98  0.42 (234) 2.10  0.59 (13) 2.01  0.44 (413)
AV velocity time integral, cm
Discharge 50.66  11.46 (18) 38.87  9.23 (208) 38.51  10.00 (328) 39.57  6.31 (23) 39.06  9.86 (577)
1 yr 51.82  12.42 (13) 43.05  10.59 (153) 40.47  10.67 (234) 40.95  14.60 (13) 41.80  11.01 (413)
AV mean gradient, mm Hg
Discharge 15.74  5.49 (18) 9.10  3.77 (208) 9.66  4.60 (328) 10.29  3.43 (23) 9.67  4.44 (577)
1 yr 11.20  4.91 (13) 9.05  4.60 (153) 8.76  4.22 (234) 9.92  5.75 (13) 8.98  4.45 (413)
AV effective oriﬁce area, cm2
Discharge 1.11  0.24 (15) 1.67  0.47 (191) 1.87  0.52 (281) 1.91  0.41 (22) 1.78  0.51 (509)
1 yr 1.36  0.45 (12) 1.70  0.46 (141) 2.01  0.54 (216) 1.98  0.39 (12) 1.87  0.54 (381)
Values are mean  SD (n).
Abbreviations as in Table 1.
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1372remains unchanged, theﬁnding of reducedAV velocity
and gradient with a higher SV suggests that EOA
increased further after discharge. A continuous
improvement in AV bioprosthesis hemodynamics after
implantation has not been documented previously in
other studies of TAVR. In fact, EOA did not change
signiﬁcantly and the mean gradient increased slightly
over the 1- to 3-year follow-up in the PARTNER trial
(1,14). There are 3 possible explanations for our ﬁnd-
ings: 1) the ﬁndings are related to a variability in
echocardiography measurement; 2) the hemodynamic
improvement is caused by increased SV that made the
EOA larger; or 3) gradual remodeling due to self-
expansion of the CoreValve is responsible for the in-
crease in EOA, reduced AV velocity, and reducedmean
gradient. Our interobserver and intraobserver vari-
ability in measuring ﬂow velocities, gradients, and
dimensions was good, and all the measurements
changed in the same direction. It would be very difﬁ-
cult to create such a consistent hemodynamic
improvement by technical measurement errors in a
large number of studies. It is possible that increased SV
enlarged the EOA, but that does not explain reduced
AV velocity, and the degree of SV changewas relatively
small during the ﬁrst month after discharge whenmost
of those improvements occurred. The increase in SV
calculation was partly related to a gradual increase in
LVOT diameter (outer-to-outer aspects of CoreValve at
the ventricular end), but LVOT VTI also increased.
When SV was calculated by the modiﬁed Simpsonvolumetric method, it also increased over 1 year after
implantation, although the increase was not statisti-
cally signiﬁcant due to a smaller increase in fewer pa-
tients (Online Figure 1). However, the amount of SV
increase fromdischarge to 1-year follow-upwas similar
between Doppler and 2-dimensional volumetric
methods (8.4 ml vs. 6.9 ml, respectively).
Therefore, we propose that the additional
improvement in AV hemodynamics over time is most
likely related to gradual self-expansion of the Cor-
eValve after implantation. The proposed mechanism
of continuous self-expansion of the bioprosthesis
could be further investigated in a prospective study
performing serial measures of EOA or bioprosthesis
perimeter by computed tomography or 3-dimensional
echocardiography. Much of our ﬁndings depend on
reliable measurements of SV, which was calculated
from LVOT diameter and VTI. LVOT diameter after
CoreValve implantation was obtained from the outer-
to-outer edge of the ventricular end of the bio-
prosthesis, as recommended by the American Society
of Echocardiography guideline for prosthetic valves.
Jilaihawi et al. (15) measured the inner-to-inner
diameter at the level of the leaﬂets in 50 CoreValve
patients in their study of patient–prosthesis
mismatch. But their method of measuring SV was not
compared with another method, and it is often difﬁ-
cult to visualize the valve leaﬂets. More comparative
studies are needed to determine the best way to
calculate SV in patients with CoreValve bioprosthesis.
FIGURE 4 SV and AV Mean Gradient Change After TAVR
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Although stroke volume (SV) increased after discharge to 1-year follow-up, the aortic valve (AV) mean gradient was signiﬁcantly reduced
(p < 0.0001) due to a further increase by CoreValve in the effective oriﬁce area after discharge. TAVR ¼ transcatheter aortic valve replacement.
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1373PARAVALVULAR AORTIC REGURGITATION. The
prevalence of AR after TAVR varies signiﬁcantly
depending on the type of prosthesis and the
method of detection (5,16). In our study, moderate-
to-severe PVAR was present in 9.9% at discharge,
which is similar to previous reports in a self-
expandable bioprosthesis (17,18). As originally
reported by Popma et al. (3), severe PVAR was
associated with worse survival in this trial with
extreme-risk patients. However, in contrast to pre-
vious reports (4,5,19), patients with mild or mod-
erate AR at discharge had similar survival as
patients with none-to-trivial AR. One possible
contributing factor to the limited association be-
tween residual mild or moderate AR and mortality
observed in this study may be the regression of AR
severity observed throughout follow-up. It is worth
noting the prevalence of competing risks in our
cohort also was likely to obscure the effects of
regurgitation and diminish the strength of the as-
sociation (1). The association between residual AR
and mortality has been deﬁned in different patient
populations and the ﬁndings presented here are not
necessarily generalizable to other risk groups for
surgical AV replacement, nor should they be inter-
preted as minimizing the well-established physio-
logical implications of residual AR.
Conﬂicting data exist about the natural history of
PVAR from post-implantation to follow-up. Thesigniﬁcant reduction in AR severity over 1-year follow-
up found in our study has not been reported by others,
although 31.9% improved in severity of PVAR over 2
years in the PARTNER trial (20,21). Possible explana-
tions for this ﬁnding of regression of PVAR are tissue
ingrowth covering the paravalvular spaces, the
continuing expansion of the nitinol frame, or also
possible aortic root remodeling. Rallidis et al. (22) fol-
lowed 40 patients with mild/moderate PVAR who had
surgical AVs at early follow-up and in 39 (97.5%) the
severity of the leaks were unchanged at 5 years.
Because tissue ingrowthwith surgical valves is an early
phenomenon, leaks that remain past this point are
generally persistent. This study indicates that the
mechanism of regression of PVAR we saw with Cor-
eValve probably has additional contributing factors
distinct from tissue ingrowth seenwith surgical valves.
A plausible explanation is that the self-expanding
nature of the CoreValve resulted in continuing out-
ward expansion and remodeling of the aortic root as
the additional contributing factor for reduced PVAR.
The signiﬁcantly increased EOA and decreased mean
gradient as well as the gradual increase, albeit very
small, in the outer-to-outer dimension of the bio-
prosthesis from discharge to 1-year follow-up are all
consistent with continuous expansion of the nitinol
frame. Additional support for this hypothesis of the
continuous expansion is provided by the observation
that patients whose PVAR regressed to none or trivial
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1374at 1 year tended to have a larger annular sizing ratio
than those who did not. When the native aortic
annulus is stretched fully, additional small outward
expansion of the CoreValve may reduce paravalvular
gap sufﬁciently to allow more tissue growth to reduce
PVAR. If the native aortic annulus is not stretched
enough, PVAR or paravalvular gaps may not regress or
close even with self-expansion of CoreValve.
PVAR remains a serious problem affecting clinical
outcome of the patients who receive TAVR. We need
to continue to improve technical expertise and valve
design to minimize PVAR after TAVR. Our ﬁnding of
regression of PVAR after CoreValve implantation
requires further validation.
STUDY LIMITATIONS. First, a main limitation is the
lack of validated quantitative criteria and volu-
metric data for assessing the severity of PVAR
associated with TAVR. Although this problem is not
unique to our study, a wrong conclusion can be
reached if there is a signiﬁcant variability among
different readers. In our study, the fact that several
physician echocardiographers assessed AR severity
could have potentially introduced variability in AR
assessment, especially mild and moderate severity,
although our physician interobserver variability in
AR assessment was good. Recently, a more granular
grading scheme using multiparametric integrative
approach has been proposed (23,24), and further
studies will be required to establish a standardized
method for assessment of PVAR after TAVR. Second,
a potential bias could exist from the echocardio-
graphy core laboratory practice that the date of a
particular study had to be known to sonographers forPERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: TAVR is
an innovative therapy for patients with severe aortic
stenosis deemed to be at high risk for surgical aortic valve
replacement. More knowledge and understanding of
natural history of TAVR are essential for appropriate use
and further improvement of TAVR.
COMPETENCY IN PATIENT CARE AND PROCE-
DURAL SKILLS: PVAR is a major problem after TAVR.
Understanding of its mechanism and clinical impact is
important in care of the patients who develop PVAR.downloading and identifying correct images in the
workstation. However, they were not aware of any
other clinical data, and studies were analyzed as they
were available. Third, echocardiography data were
not available in all patients at all follow-ups. There-
fore, we analyzed paired data, which showed similar
results to the data analyzed for all patients. Lastly,
when feasible, we deﬁned severe PVAR as a >20%
circumferential extent as recommended in the orig-
inal VARC. If we were to use the VARC-2 recom-
mendation, the percentage of the patients with
severe AR decreases slightly, but the overall conclu-
sions are unchanged.
CONCLUSIONS
After TAVR with the CoreValve bioprosthesis in
extreme-risk patients with severe AS, there was a
further AV hemodynamic improvement after
discharge resulting in a signiﬁcantly larger EOA and
lower aortic valve gradient at 1-year follow-up
compared with discharge. There was also a signiﬁ-
cant regression of PVAR over time up to 1 year. This
is possibly related to continuous expansion of the
CoreValve with nitinol frame resulting in the remod-
eling of aortic root.
ACKNOWLEDGMENT The authors thank Jane Moore,
MS, ELS, an employee of Medtronic, for providing
copyediting assistance and ﬁgure generation.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Jae K. Oh, Mayo Clinic, Gonda 6210, 200 1st Street,
SW, Rochester, Minnesota 55905. E-mail: oh.jae@
mayo.edu.COMPETENCY IN INTERPERSONAL AND COMMU-
NICATION SKILLS: TAVR requires the strong team work
of a heart team comprising a surgeon, interventionalist,
imager, and clinicians involved in patient care. It is
important for the team to communicate potential risks
and beneﬁts of this new therapeutic procedure.
TRANSLATIONAL OUTLOOK: In this study, we are
reporting on patients with aortic stenosis at extreme
surgical risk and 1-year follow-up. A longer follow-up
in this patient population and studies in different
populations will be necessary to obtain comprehensive
knowledge about the hemodynamics and PVAR after
TAVR.
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